Physician profile
Peter Agaba
NPI 1851952592
$3,641.38
in general payments reported to CMS, 2019-2025
34 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.01 · 2020: $15.13 · 2021: $147 · 2022: $430 · 2023: $1,110 · 2024: $1,082 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.98 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $786.33 | 2022-2025 | Airsupra, Farxiga |
| Abbvie INC. | $457.87 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $453.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $199.34 | 2023-2024 | Vyepti |
| Amgen INC. | $183.65 | 2022-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $175.35 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $150.61 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $150.17 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $145.14 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.64 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $106.88 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.25 | 2025 | Caplyta |
| Aimmune Therapeutics, INC. | $61.08 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $59.02 | 2023-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $52.14 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.41 | 2019-2023 | Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $50.25 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $45.84 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $32.55 | 2024 | Strensiq |
| Ethicon US, LLC | $31.94 | 2022 | |
| Shield Therapeutics INC | $28.40 | 2023 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $23.36 | 2021 | |
| Inspire Medical Systems, INC. | $21.75 | 2024 | Inspire |
| Averitas Pharma INC. | $21.63 | 2024 | Qutenza |
| Horizon Therapeutics Plc | $19.65 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.28 | 2024 | Keveyis |
| Janssen Pharmaceuticals, INC | $18.10 | 2023 | Xarelto |
| Digestive Care, INC. | $17.21 | 2024 | Pertzye |
| Abbott Laboratories | $16.49 | 2023 | Freestyle Libre 3 |
| Insulet Corporation | $16.43 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.99 | 2024 | Xifaxan |
| Smith+Nephew, INC. | $15.13 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 2023 | Camzyos |
| Idorsia Pharmaceuticals US INC | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Agaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.